Original Article

Hsa_circ_0007534 as a blood-based marker for the diagnosis of colorectal cancer and its prognostic value

Wanchuan Zhang1*, Shihua Yang1*, Yanlong Liu2, Yongpeng Wang1, Tao Lin1, Yanxi Li1, Rui Zhang1

1Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China; 2Department of Colorectal Surgery, Harbin Medical University Cancer Hospital, Harbin, China. *Equal contributors.

Received November 28, 2017; Accepted December 22, 2017; Epub March 1, 2018; Published March 15, 2018

Abstract:
Background: Many studies have shown that differentially expressed circular RNA (circRNA) in plasma can serve as biomarkers in non-invasive detection of cancers during screening. However, the clinical significance of plasma circRNA in the diagnosis of colorectal cancer (CRC) is still not clear. Therefore, we examined expression of hsa_circ_0007534 in plasma to verify whether it can be utilized to diagnose and monitor CRC in routine clinical practice. Methods: 112 CRC patients and 46 healthy controls were recruited to participate in our study. The levels of hsa_circ_0007534 in plasma samples and tumor tissues were identified by real-time quantitative polymerase chain reaction (RT-qPCR). The diagnostic value was evaluated using receiver operating characteristics (ROC) curves and the area under the ROC curves (AUC). The Kaplan-Meier survival curve was used to evaluate whether the expression level of hsa_circ_0007534 was associated with overall survival rate. Results: Compared with the healthy control group, hsa_circ_0007534 expression was significantly increased in plasma from CRC patients. Increased hsa_circ_0007534 expression level in plasma was associated with progression of clinical classifications, metastatic phenotype, and poor differentiation in CRC patients. ROC analysis showed that hsa_circ_0007534 could distinguish CRC patients from healthy controls with high AUC (0.780), sensitivity (0.92) and specificity (0.522). Finally, high hsa_circ_0007534 expression was positively correlated with poor prognosis in CRC patients. Conclusion: All of the results suggest that hsa_circ_0007534 may be a potential cancer marker of patients with CRC and may associate with poor prognosis.

Keywords: Colorectal cancer, circular RNA, biomarker, diagnosis, prognosis

Introduction

Colorectal cancer (CRC) is the fourth most common malignant gastrointestinal cancer and accounts for approximately 9% of all cancer cases. The incidence of CRC is more than 376,000 and corresponded to about 191,000 deaths in China by 2015 [1]. In the past few decades, colonoscopy has been the dominant and preferred screening modality for CRC worldwide, and surgical resection is the ultimate therapeutic treatment [2]. However, current methods of screening have been far from adequate in building a complete early-warning system and prognostic value for CRC patients. Previous studies suggested that early diagnosis and treatment have improved patient outcomes, which largely depended on the stage of the tumor at the time of detection, and for CRC patients with advanced stage disease, prognosis remained quite poor [3-5]. In addition, prognostic markers can facilitate stratification of CRC patients in that it is beneficial to monitor tumor recurrence and metastasis [6]. Therefore, exploring novel and specific biomarkers is an imperative need for improving the current diagnostic and prognostic tools for CRC patients.

Circular RNA (circRNA) is a class of endogenous non-coding RNA and exists ubiquitously in the cytoplasm of eukaryotic cells [7, 8]. CircRNA is generally formed by back-splicing with high stability, covalently closed continuous loop, without 5’ to 3’ polarity and polyadenylated tail, endowing them with a stable structure to counteract RNA exonucleolytic digestion [9, 10]. CircRNAs perform a wide variety of biological functions in eukaryotic cells primarily through com-
peting endogenous RNAs (ceRNAs) or miRNA sponges [11]. Recently, emerging evidence has revealed that circRNAs are stably present in body fluid and can serve as novel non-invasive biomarkers in various diseases, including arthritis [12], pre-eclampsia [13] and malignancies [14, 15]. It is established that abnormally expressed circRNAs are strongly linked to the progression and development of CRC [16-18]. Hsa_circ_0003906 is dramatically downregulated in CRC tumor tissues and significantly correlates with lymphatic metastasis and poor differentiation, suggesting that hsa_circ_0003906 may serve as a potential biomarker for the diagnosis of CRC [19]. To the best of our knowledge, there is little literature focused on the blood-based non-invasive detection of CRC.

Hsa_circ_0007534 is located in chr17: 61869771-61877977, the spliced sequence length is 400 nt, and its associated-gene symbol is DDX42 (DEAD-box helicase 42; circBase database, http://www.circbase.org/). Based on our previous results, we first verified that hsa_circ_0007534 was significantly upregulated in CRC cell lines and tumor tissues. Then, we hypothesized that hsa_circ_0007534 might be released into circulation during CRC initiation and could be utilized to detect and monitor CRC. To validate the hypothesis, first, the expression levels of hsa_circ_0007534 in plasma needed to be addressed; second, we performed a correlation analysis between plasma and tumor tissues hsa_circ_0007534 level to confirm the accuracy of a blood-based tumor marker; third, the receiver operating characteristics (ROC) curves and the area under the ROC curves (AUC) were calculated to investigate the clinical diagnostic significance of hsa_circ_0007534; fourth, Kaplan-Meier survival curve was used to evaluate whether the expression level of hsa_circ_0007534 was associated with overall survival rate.

Material and methods

Patients and specimens

112 CRC patients and 46 healthy controls were recruited from the Cancer Hospital of China Medical University (Shenyang, China). 112 pairs of tumor tissue and matched adjacent non-tumorous tissues were collected from CRC patients who had undergone surgery at the Cancer Hospital of China Medical University (Shenyang, China) between January 2014 and June 2016. None of the patients were subjected to preoperative radiotherapy or chemotherapy and diagnosed with CRC based on histopathological evaluation. All collected tissue samples were immediately stored in liquid nitrogen. 10 mL of blood samples from preoperative and postoperative CRC patients were collected with ethylenediaminetetraacetic acid (EDTA)-containing tubes (Becton, Dickinson and Company), plasma samples were separated immediately, as described previously [20], and stored at -80°C in an ultra-low temperature refrigerator. Human samples were obtained with written informed consent from all of the patients. The study was approved by the Ethics Committee of the Department of Colorectal Surgery, Cancer Hospital of China Medical University (Shenyang, China).

Total RNA extraction

RNA extraction from tumor tissue, non-tumorous tissue, and plasma was performed using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) and preserved at -80°C until the time of usage. RNA concentration was measured using NanoDrop ND-2000 (Thermo Fisher Scientific, Wilmington, DE, USA).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Moloney Murine Leukemia Virus reverse transcriptase (Promega Corporation, Madison, WI, USA) was used to synthesize cDNA. Divergent primers were designed to amplify the head-to-tail splicing of circRNA using an ABI7300 System (Applied Biosystems, Foster City, CA, USA) with SYBR Select Master Mix (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was utilized to normalize the expression of the circRNAs. The PCR primers were used in this study as follows: hsa_circ_0007534, forward 5'-GTGACGGAAATCAATGCACC-3' and reverse 5'-ATGGAATTGCGAGTG-3'; GAPDH, forward 5'-GCACCGTGAGCTGAA-3' and reverse 5'-TGTTGAGACGCGCTGGA-3'. The relative expression levels of hsa_circ_0007534 were calculated using the 2^(-ΔΔCt) method [21].

Statistical analysis

Data were presented as the mean ± standard deviation (SD) for each group. All statistical
analyses were performed using PRISM version 7.0 (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA). Student’s t-test was used to analyze the two-group differences. Inter-group differences were analyzed by one-way analysis of variance, followed by a post hoc Tukey’s test for multiple comparisons. Pearson χ² tests were used to evaluate differences in the clinical characteristics between the two groups. Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were used to assess the ability of using plasma hsa_circ_0007534 as a diagnostic tool for CRC patients. Spearman’s Rank analysis was used to identify the correlation of hsa_circ_0007534 levels between plasma and tumor tissues. A Bland-Altman plot (difference plot) was used to analyze the agreement of hsa_circ_0007534 levels between plasma and tumor tissues. Survival analysis was performed using the Kaplan-Meier method with the log-rank test applied for comparison. *P < 0.05, **P < 0.01, ***P < 0.001.

Results

Expression of hsa_circ_0007534 in tumor tissues and plasma from CRC patients

RT-qPCR analysis of tumor tissue and non-tumor adjacent tissue from 112 CRC patients
showed that 78 of these cases (69.6%) exhibited upregulation of hsa_circ_0007534 levels in tumor tissues (Figure 1A). To validate whether differentially expressed hsa_circ_0007534 in plasma could serve as a potential biomarker for CRC detection, RT-qPCR was also performed on plasma from 112 CRC patients and 46 healthy controls. Consistent with the results using tumor tissue, we found that the levels of hsa_circ_0007534 in the plasma from CRC patients were significantly increased compared with those of the healthy control (Figure 1B). Increased hsa_circ_0007534 expression level in plasma was associated with the progression of T classifications (Figure 1C), N classifications (Figure 1D), metastatic phenotype (Figure 1E) and poor differentiation (Figure 1F) in CRC patients. These findings suggest a link between upregulation of hsa_circ_0007534 and the aggressive characteristics of CRC.

Correlation between clinical parameters and plasma hsa_circ_0007534

To verify whether hsa_circ_0007534 can serve as a biomarker for predicting clinical outcomes in CRC patients, we performed the correlation analysis between clinical parameters and plasma hsa_circ_0007534 levels. 112 CRC patients were divided into 2 groups: a high expression group (n = 72) and a low expression group (n = 40). The levels of hsa_circ_0007534 in plasma had no significant relationship to age and gender (Table 1). In addition, the high hsa_circ_0007534 expression group exhibited a significantly higher incidence of poor differentiation, distant metastasis, and clinical classifications than the low hsa_circ_0007534 expression group (Table 1). Previous studies have reported that both poor differentiation and metastatic phenotype are the independent risk factors for CRC patient survival [19]. Our results indicate that hsa_circ_0007534 as an oncogene can promote CRC progression and lead to a poor prognosis.

Correlation of hsa_circ_0007534 expression between plasma and tumor tissues

To further confirm the reliability of a blood-based marker for CRC diagnosis, we performed a correlation analysis of hsa_circ_0007534 expression between plasma samples and tumor tissues from CRC patients. Hsa_circ_0007534 expression levels obtained from plasma samples and tumor tissues were strongly correlated (r = 0.505, P < 0.001; mean differences = -0.551 ± 0.913; Figure 2A and 2B). To investigate whether tumor resection can regulate plasma hsa_circ_0007534 levels, RT-qPCR was carried out to investigate the expression of hsa_circ_0007534 in plasma from CRC patients before tumor resection and 14 days after tumor resection. As expected, the data showed that plasma levels of hsa_circ_0007534 significantly declined 14 days after tumor resection compared with levels before surgery (Figure 2C). Furthermore, the stability of hsa_circ_0007534 in plasma was investigated and the results showed that hsa_circ_0007534 was relatively stable within nine hours at room temperature. However, with the extension of incubation time, the expression levels of hsa_circ_0007534 significantly decreased compared with the control group (Figure 2D). These results suggest that hsa_circ_0007534 is relatively stable in plasma samples and can effectively reflect the actual yield of hsa_circ_0007534 in tumor tissues. Therefore, this evidence strongly demonstrates that plasma-based hsa_circ_0007534 can serve as a tumor marker for CRC screening.

Table 1. Correlation between hsa_circ_0007534 levels and clinical parameters

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Hsa_circ_0007534 expression</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 60</td>
<td>33</td>
<td>17</td>
</tr>
<tr>
<td>&gt; 60</td>
<td>39</td>
<td>23</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>40</td>
<td>28</td>
</tr>
<tr>
<td>Female</td>
<td>32</td>
<td>12</td>
</tr>
<tr>
<td>T classification</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>58</td>
<td>15</td>
</tr>
<tr>
<td>III-IV</td>
<td>14</td>
<td>25</td>
</tr>
<tr>
<td>N classification</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>40</td>
<td>14</td>
</tr>
<tr>
<td>1-2</td>
<td>32</td>
<td>26</td>
</tr>
<tr>
<td>Distant metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>48</td>
<td>19</td>
</tr>
<tr>
<td>Yes</td>
<td>24</td>
<td>21</td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well-moderate</td>
<td>50</td>
<td>6</td>
</tr>
<tr>
<td>Poor</td>
<td>22</td>
<td>34</td>
</tr>
</tbody>
</table>
The diagnostic value of hsa_circ_0007534 in CRC diagnosis

To further estimate the diagnostic value of hsa_circ_0007534 in CRC patients, ROC curves and the area under the ROC curves (AUC) were performed in all of the participants, including 112 CRC patients and 46 healthy controls. The ROC curves showed that hsa_circ_0007534 was a strong distinguishing mark between the CRC patients and healthy controls, with an AUC of 0.780 (95% CI: 0.703-0.857; \( P < 0.001 \); Figure 3A and Table 2). The sensitivity and specificity were 0.920 and 0.522, respectively. The fundamental aim of this study was to diagnose CRC patients at the early stage. Therefore, the ROC curves were performed in different clinical stages. The AUC for stage I (Figure 3B), II (Figure 3C), III (Figure 3D) or IV (Figure 3E) was 0.721, 0.739, 0.871 or 0.890, respectively. Although hsa_circ_0007534 had the highest diagnostic value for CRC patients with stage IV, detecting plasma hsa_circ_0007534 might be helpful for differentiating stage I CRC patients from healthy control.

The prognostic value of hsa_circ_0007534 in CRC patients

Kaplan-Meier analysis was performed to evaluate whether plasma hsa_circ_0007534 levels can predict a CRC prognosis. CRC patients were segregated into a hsa_circ_0007534 high expression group and a low expression group according to \( \log_{2} FC \geq 1 \). CRC patients with high hsa_circ_0007534 levels had a significantly poorer prognosis than that of patients with low hsa_circ_0007534 levels (\( P = 0.048 \); Figure 4).

Discussion

Accumulating evidence suggests that cell-free nucleic acids are detectable in plasma and serum of cancer patients and can serve as biomarkers for cancer diagnosis, including esophageal squamous cell carcinoma [22], bladder cancer [23], epithelial ovarian cancer [24] and lung cancer [25]. Although numerous studies have focused on DNA, mRNA, microRNAs, and long non-coding RNA as potential tumor markers for cancer screening [26], plasma circRNAs as diagnostic and prognostic markers for CRC have seldom been reported.

In our study, CRC-related circRNA was screened based on different expression profiling between CRC tumorous tissues and adjacent non-tumorous tissues than in our previous study, which was not published. Hsa_circ_0007534 was identified and significantly upregulated in CRC tumorous tissues, and then we further measured its expression level in plasma from CRC patients and healthy subjects. Our findings suggest that the levels of hsa_circ_0007534 are significantly upregulated in plasma from CRC.
Hsa_circ_0007534 in CRC diagnosis

patients compared with the healthy control group, indicating strong evidence that hsa_circ_0007534 can be detected in plasma and can serve as a diagnostic marker for CRC.

Blood-based nucleic acids are considered to be unstable, which is attributed to the high level of RNase activity in plasma. Increased plasma RNase activity has been confirmed in patients with malignancies [27]. To verify the stability of hsa_circ_0007534 in plasma from CRC patients, we performed an experiment in that plasma samples were stored at room temperature for different times. The results demonstrated that hsa_circ_0007534 was relatively stable existing at room temperature for nine hours. The precise mechanism of circRNAs resistance to endogenous RNase may be closely related to its closed continuous cyclic structure [14]. Therefore, hsa_circ_0007534 serving as a promising CRC biomarker is reasonable in routine clinical practice.

One of the major goals of the current study was to diagnose CRC patients at the earliest stage possible, which may increase success in clinical treatment and may be beneficial in improving overall survival [28]. Therefore, the diagnostic value of hsa_circ_0007534 in different clinical stages was investigated in all of the subjects, including 112 CRC patients and 46 healthy controls. The ROC curves illustrated strong diagnostic value (AUC = 0.780; 95% CI: 0.703-0.857; \( P < 0.001 \)) for CRC patients from all of the subjects. Interestingly, the diagnostic value of hsa_circ_0007534 could distinguish stage I patients from healthy control with an AUC of 0.721 (95% CI: 0.611-0.831; \( P < 0.001 \)), which is similar in stage I-IV patients. In general, hsa_circ_0007534 provided high diagnostic power for the detection of CRC in patients and plasma hsa_circ_0007534 could serve as a promising tumor marker for the early diagnosis of CRC.

The distant metastasis and TNM stages are the most important parameters in the evaluation of the prognosis of patients with CRC [29]. Zhuo, et al. showed that the downregulation of circRNA0003906 levels significantly correlated with lymphatic metastasis and poor differentiation in CRC patients [19]. Moreover, Wang, et al. indicated that hsa_circ_001988 was significantly correlated with differentiation and peri-neural invasion in CRC patients [30]. In our study, we found that there was a significant relationship between high expression levels of hsa_circ_0007534 in plasma from CRC patien-
Hsa_circ_0007534 in CRC diagnosis

Table 2. Clinical diagnostic significance of hsa_circ_0007534 in CRC patients

<table>
<thead>
<tr>
<th>Stage</th>
<th>AUC</th>
<th>P-value</th>
<th>95% CI</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Youden index</th>
<th>Cut-off Lower</th>
<th>Cut-off Upper</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I-IV</td>
<td>0.780</td>
<td>&lt; 0.001</td>
<td>0.703</td>
<td>0.857</td>
<td>0.920</td>
<td>0.522</td>
<td>0.442</td>
<td>1.225</td>
</tr>
<tr>
<td>Stage I</td>
<td>0.721</td>
<td>&lt; 0.001</td>
<td>0.611</td>
<td>0.831</td>
<td>0.816</td>
<td>0.565</td>
<td>0.381</td>
<td>1.290</td>
</tr>
<tr>
<td>Stage II</td>
<td>0.739</td>
<td>&lt; 0.001</td>
<td>0.631</td>
<td>0.846</td>
<td>0.886</td>
<td>0.565</td>
<td>0.451</td>
<td>1.290</td>
</tr>
<tr>
<td>Stage III</td>
<td>0.871</td>
<td>&lt; 0.001</td>
<td>0.785</td>
<td>0.957</td>
<td>0.727</td>
<td>0.891</td>
<td>0.618</td>
<td>2.060</td>
</tr>
<tr>
<td>Stage IV</td>
<td>0.890</td>
<td>&lt; 0.001</td>
<td>0.797</td>
<td>0.983</td>
<td>0.706</td>
<td>0.978</td>
<td>0.684</td>
<td>2.470</td>
</tr>
</tbody>
</table>

Figure 4. The prognostic value of hsa_circ_0007534 in CRC patients. Kaplan-Meier survival curve was used to evaluate whether hsa_circ_0007534 expression levels were associated with overall survival rate in patients with CRC.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (Grant No. 81402367), “Liaoning BaiQianWan Talents Program” (Grant No. [2017] No. B44), Liaoning Clinical Research Center for Colorectal Cancer (Grant No. 2015225005) and Clinical Capability Construction Project for Liaoning Provincial Hospitals (Grant No. LNCCC-D44-2015).

Disclosure of conflict of interest

None.

References


Address correspondence to: Dr. Rui Zhang, Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, 44 Xiaoheyan Road, Dadong District, Shenyang 110042, Liaoning, China. Tel: (86)24-319-16293; Fax: (86)024-24315679; E-mail: ruizhangc-mu@aliyun.com


